Intravitreal Cidofovir (HPMPC) Treatment of Cytomegalovirus Retinitis in Patients with Acquired Immune Deficiency Syndrome

Ophthalmology

Volumn 102, Issue 4, 1995, Pages 533-543

  Kirsch, Leonard S ^a   Arevalo, J Fernando ^a   de la Paz, Eugenio Chavez ^a   Munguia, David ^a   de Clerq, Erik ^b   Freeman, William R ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CIDOFOVIR; PROBENECID;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; DISEASE COURSE; DRUG EFFICACY; FEMALE; HUMAN; INTRAOCULAR PRESSURE; IRITIS; MALE; PRIORITY JOURNAL; RETINITIS; UVEITIS;

EID: 0028902311     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-6420(95)30985-2     Document Type: Article

References (42)

1. Long-term visual morbidity of cytomegalovirus retinitis in patients with acquired immune deficiency syndrome
2. A prospective study of the ophthalmologic findings in the acquired immune deficiency syndrome
3. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine
4. Ophthalmic involvement in acquired immunodeficiency syndrome
5. Progression rates of cytomegalovirus retinopathy in ganciclovir-treated and untreated patients
6. Longitudinal study of cytomegalovirus retinitis in acquired immune deficiency syndrome
7. Acquired immune deficiency syndrome: ocular manifestations
8. Acquired immune deficiency syndrome. Pathogenic mechanisms of ocular disease
9. Ocular manifestations of acquired immune deficiency syndrome
10. Cytomegalovirus retinitis and acquired immunodeficiency syndrome
11. A novel selective broad-spectrum anti-DNA virus agent
12. Selective inhibition of human cytomegalovirus DNA synthesis by (S) 1-(3-hydroxy2-phosphonylmethoxypropyl) cytosine {(S)-HPMPC) and 9-(1,3-dihydroxy-2-propoxymethyl) guanine (DHPG)
13. Comparative activity of selected antiviral compounds against clinical isolates of human cytomegalovirus
14. Comparative inhibitory effects of nucleoside analogues on different clinical isolates of human cytomegalovirus in vitro
15. Activity of (S)-1-(3-hydroxy2-phosphonylmethoxypropyl) cytosine (HPMPC) against guinea pig cytomegalovirus infection in cultured cells and in guinea pigs
16. Therapeutic potential of HPMPC as an antiviral drug
17. Evaluation of HPMPC therapy for primary and recurrent genital herpes in mice and guinea pigs
18. The safety, pharmacokinetics and anti-CMV activity of weekly HPMPC in HIV positive patients excreting CMV
19. New visual acuity charts for clinical research
20. in collaboration with the AIDS Clinical Trials Group (ACTG). Studies of Ocular Complications of AIDS foscarnet-ganciclovir cytomegalovirus retinitis trial: 1. Rationale, design, and methods
21. (S)-1-(3-hydroxy2-phosphonylmethoxypropyl) cytosine, a potent and selective inhibitor of human cytomegalovirus replication
22. Useful adjuncts for vitreoretinal surgery
23. Nonparametric estimation from incomplete observations
24. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis
25. Treatment of cytomegalovirus retinopathy in patients with acquired immunodeficiency syndrome. Use of the experimental drug 9-[2-hydroxy-l-(hydroxymethyl)ethoxymethyl]guanine
26. Treatment of cytomegalovirus retinitis with ganciclovir
27. Intravenous and intraocular ganciclovir for CMV retinitis in patients with AIDS or chemotherapeutic immunosuppression
28. A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS
29. Pathophysiology and treatment of clinically resistant cytomegalovirus retinitis
30. Combination ganciclovir and foscarnet in the treatment of clinically resistant cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome
31. Foscarnet treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome
32. Ef ficacy and tolerance of intravitreal ganciclovir in cytomegalovirus retinitis in acquired immune deficiency syndrome
33. Survival of patients with the acquired immune deficiency syndrome after development of cytomegalovirus retinopathy
34. Use of intravitreal ganciclovir (dihydroxy propoxymethyl guanine) for cytomegalovirus retinitis in a patient with AIDS
35. Treatment of cytomegalovirus retinitis with intravitreal ganciclovir
36. Sustained-release ganciclovir therapy for treatment of cytomegalovirus retinitis: use of an Intravitreal device
37. Treatment of cytomegalovirus retinitis with intravitreal injection of liposome encapsulated ganciclovir in a patient with AIDS
38. Long-acting therapy of viral retinitis with (S)-103(3-hydroxy-2-phosphonylmethoxypropyl) cytosine
39. Lack of retinal toxicity of the anticytomegalovirus drug (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine
40. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis
41. Longitudinal study of cytomegalovirus retinitis in acquired immune deficiency syndrome